RT Journal Article
SR Electronic
T1 Single-cell profiling reveals the sustained immune infiltration, surveillance, and tumor heterogeneity of infiltrative BCC
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.22.22278093
DO 10.1101/2022.08.22.22278093
A1 Huang, Lingjuan
A1 Wang, Xianggui
A1 Pei, Shiyao
A1 Li, Xin
A1 Dong, Liang
A1 Bian, Xiaohui
A1 Sun, Hongyin
A1 Jin, Liping
A1 Hou, Huihui
A1 Shi, Wensheng
A1 Zhang, Xiyuan
A1 Zhang, Lining
A1 Zhao, Shuang
A1 Chen, Xiang
A1 Yin, Mingzhu
YR 2022
UL http://medrxiv.org/content/early/2022/08/25/2022.08.22.22278093.abstract
AB Background Infiltrative basal cell carcinoma (iBCC) is a particularly aggressive subtype of BCC that tends to recur after surgery, and its progression and malignancy are closely related to its interaction with the local tumor microenvironment (TME).Methods Here, we performed single-cell RNA sequencing (scRNA-seq) from 5 patients to determine the dynamic changes of TME between iBCC and adjacent normal skin (ANS).Results We found active immune collaborations among CXCL13+ follicular helper-like T cells (Tfh-like cells), SPP1+CXCL9/10high Macro1, and plasma cells, which were enriched in iBCC. Specifically, SPP1+CXCL9/10high Macro1 could activate plasma cells by BAFF signaling, and Tfh-like cells potentially recruited B/Plasma cells through CXCL13. The proinflammatory SPP1+CXCL9/10high Macro1 and angiogenesis-related SPP1+CCL2high Macro1 were characterized, revealing their heterogeneous phenotype within the TME. We also discovered a novel iBCC-enriched ANGPT2+ lymphatic endothelial cell (LEC) subtype with strong abilities to promote leukocyte migration and activation. Interestingly, we found upregulation of MHC-I molecules in fibroblasts in iBCC compared to those in ANS. However, we found that MDK signals derived from malignant basal cells (MBCs) were markedly increased, and their expression was an independent factor in predicting the infiltration depth of iBCC, emphasizing its role in driving malignancy and remodeling the TME. Additionally, we identified differentiation-associated SOSTDC1+IGFBP5+CTSV+ MB1 and epithelial mesenchyme transition (EMT)-associated TNC+SFRP1+CHGA+ MB2. The components of the two heterogeneous subpopulations in the TME might be effective predictors of the malignancy and prognosis of iBCC.Conclusions Altogether, our study is beneficial for understanding the cellular heterogeneity involved in the pathogenesis of iBCC and provides potential therapeutic targets for clinical research.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from General Program, The National Natural Science Foundation of China (No. 81874138 and 82073020), Hunan Natural Science Foundation for Distinguished Young Scholars (No. 2021JJ10073), The Natural Science Foundation of Hunan Province of China (No. 2021JJ31103), The Youth Science Foundation of Xiangya Hospital (No. 2021Q10).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients were from Xiangya Hospital of Central South University and signed an informed consent form for providing samples. Our study was approved by the institutional ethics committe of Xiangya Hospital of Central South University (2022020109).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe IHC results generated during this study are provided as supplementary tables. single-cell transcriptome and additional datasets are available upon request.